The Scent of Disease: Human Body Odor Contains an Early Chemosensory Cue of Sickness by Olsson, Mats J. et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
USDA National Wildlife Research Center - Staff
Publications
U.S. Department of Agriculture: Animal and Plant
Health Inspection Service
3-12-2014
The Scent of Disease: Human Body Odor
Contains an Early Chemosensory Cue of Sickness
Mats J. Olsson
Johan N. Lundstrom
Bruce A. Kimball
USDA APHIS Wildlife Services, bruce.kimball@ars.usda.gov
Amy R. Gordon
Bianka Karshikoff
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/icwdm_usdanwrc
Part of the Life Sciences Commons
This Article is brought to you for free and open access by the U.S. Department of Agriculture: Animal and Plant Health Inspection Service at
DigitalCommons@University of Nebraska - Lincoln. It has been accepted for inclusion in USDA National Wildlife Research Center - Staff Publications
by an authorized administrator of DigitalCommons@University of Nebraska - Lincoln.
Olsson, Mats J.; Lundstrom, Johan N.; Kimball, Bruce A.; Gordon, Amy R.; Karshikoff, Bianka; Hosseini, Nishteman; Sorjonen,
Kimmo; Hoglund, Caroline Olgart; Solares, Carmen; Soop, Anne; Axelsson, John; and Lekander, Mats, "The Scent of Disease: Human
Body Odor Contains an Early Chemosensory Cue of Sickness" (2014). USDA National Wildlife Research Center - Staff Publications.
1412.
http://digitalcommons.unl.edu/icwdm_usdanwrc/1412
Authors
Mats J. Olsson, Johan N. Lundstrom, Bruce A. Kimball, Amy R. Gordon, Bianka Karshikoff, Nishteman
Hosseini, Kimmo Sorjonen, Caroline Olgart Hoglund, Carmen Solares, Anne Soop, John Axelsson, and Mats
Lekander
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/icwdm_usdanwrc/
1412
 http://pss.sagepub.com/
Psychological Science
 http://pss.sagepub.com/content/25/3/817
The online version of this article can be found at:
 
DOI: 10.1177/0956797613515681
 2014 25: 817 originally published online 22 January 2014Psychological Science
Sorjonen, Caroline Olgart Höglund, Carmen Solares, Anne Soop, John Axelsson and Mats Lekander
Mats J. Olsson, Johan N. Lundström, Bruce A. Kimball, Amy R. Gordon, Bianka Karshikoff, Nishteman Hosseini, Kimmo
The Scent of Disease: Human Body Odor Contains an Early Chemosensory Cue of Sickness
 
 
Published by:
 http://www.sagepublications.com
On behalf of:
 
 
 Association for Psychological Science
 can be found at:Psychological ScienceAdditional services and information for 
 
 
 
 
 http://pss.sagepub.com/cgi/alertsEmail Alerts: 
 
 http://pss.sagepub.com/subscriptionsSubscriptions:  
 http://www.sagepub.com/journalsReprints.navReprints: 
 
 http://www.sagepub.com/journalsPermissions.navPermissions: 
 
 What is This?
 
- Jan 22, 2014OnlineFirst Version of Record 
 
- Mar 12, 2014Version of Record >> 
 at NATIONAL AGRICULTURAL LIBRARY on April 30, 2014pss.sagepub.comDownloaded from 
Psychological Science
2014, Vol. 25(3) 817 –823
© The Author(s) 2014
Reprints and permissions: 
sagepub.com/journalsPermissions.nav
DOI: 10.1177/0956797613515681
pss.sagepub.com
Research Report
Diagnosis of ailments based on tasting and smelling 
bodily fluids goes back to ancient history. More recently, 
several diseases have been reported to yield characteris-
tic odors, such as Scrofula (which smells like stale beer), 
Typhoid fever (which smells like baked bread) and 
Yellow fever (which smells like a butcher’s shop; Penn & 
Potts, 1998). Today, the idea of medical diagnosis of 
infectious diseases and other disorders through analysis 
of volatile organic compounds from skin, breath, feces, 
or urine by aid of electronic noses has refocused atten-
tion on these observations, and the results hold promise 
for disease-specific volatile biomarkers to be of wide-
spread clinical use in the future (Shirasu & Touhara, 
2011).
In rodents, a wide array of infections, ranging from 
gastrointestinal nematodes to viruses, are known to alter 
body odor. This alteration results in a lowered preference 
for the infected individual during initial investigation 
(Ehman & Scott, 2001, 2002; Kiesecker, Skelly, Beard, & 
Preisser, 1999). Chemosensory-mediated avoidance of 
sick conspecifics in animals is now well established 
(Arakawa, Cruz, & Deak, 2011; Kavaliers & Colwell, 
1995a, 1995b). To investigate whether the first line of 
defense to microbes entails detectable chemosensory 
sickness cues, researchers in animal studies have used 
lipopolysaccharide (LPS) to activate the innate immune 
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Abstract
Observational studies have suggested that with time, some diseases result in a characteristic odor emanating from 
different sources on the body of a sick individual. Evolutionarily, however, it would be more advantageous if the 
innate immune response were detectable by healthy individuals as a first line of defense against infection by various 
pathogens, to optimize avoidance of contagion. We activated the innate immune system in healthy individuals by 
injecting them with endotoxin (lipopolysaccharide). Within just a few hours, endotoxin-exposed individuals had a 
more aversive body odor relative to when they were exposed to a placebo. Moreover, this effect was statistically 
mediated by the individuals’ level of immune activation. This chemosensory detection of the early innate immune 
response in humans represents the first experimental evidence that disease smells and supports the notion of a 
“behavioral immune response” that protects healthy individuals from sick ones by altering patterns of interpersonal 
contact.
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system and an inflammatory response (Beutler, 2009; 
Suffredini, Fantuzzi, Badolato, Oppenheim, & O’Grady, 
1999). Indeed, in the rat, it has been shown that LPS 
injection influences the body odor of an individual such 
that other rats avoid contact (Arakawa, Blandino, & Deak, 
2009; Dantzer, 2009). Therefore, the innate immune 
response is also relevant to the investigation of olfactory 
markers in humans.
With this background, we set out to—for the first 
time—experimentally test the idea of a chemosensory 
sickness cue in humans. We hypothesized that humans 
are able to perceptually dissociate between healthy and 
sick individuals’ body odors. Moreover, under the 
assumption that this capacity has evolved to reduce con-
tamination risks, we hypothesized that it should be pres-
ent at an early stage of the sickness response. We tested 
this hypothesis by comparing body-odor samples from 
individuals following LPS treatment to samples from the 
same individuals following saline treatment. Because 
inflammatory cytokines are involved in sickness behavior 
(Avitsur, Cohen, & Yirmiya, 1997) and are also implicated 
in the expression of aversive odor cues in response to a 
number of pathogens in animals (Dantzer, 2004), we 
measured proinflammatory cytokines as key mediators of 
these odor cues.
Method
Sampling of body odors
Eight healthy volunteers (7 men, 1 woman; mean age = 
24 years, SD = 3.71) were recruited for donation of body 
odor during two sessions. To be included in the study, 
participants had to be between 18 and 45 years old, right-
handed, and nonsmoking and to neither be taking medi-
cation (including nonbarrier contraceptives for female 
participants) nor have a history of drug abuse, chronic 
pain, or psychiatric disorders. The eight donors took part 
in two sessions, both conducted at 1 p.m. and separated 
by 28 days, in which they received either LPS or saline 
injections. Participants wore tight T-shirts to allow for 
body-odor sampling. The sampling took place in a hos-
pital environment and lasted for a total of 4 hr. A physi-
cian supervised the donors (for details, see Body-Odor 
Sampling in the Supplemental Material available online). 
The study was approved by the regional ethical review 
board in Stockholm. Written informed consent was 
obtained from all participants.
Measures of sickness response
During the sampling period, tympanic temperature was 
measured (using a Thermoscan PRO-1; Braun, Inc., San 
Diego, CA) before injection and once every hour following 
injection. Four hours after injection with LPS, participants’ 
body temperature had increased by about 1 °C (Fig. 1d). 
Plasma samples were provided 0 hr (baseline), 1 hr, 1.5 hr, 
2 hr, 3 hr, and 4 hr after injection; they were frozen at −70 
°C and were later thawed for analysis with Millipore’s 
MILLIPLEX MAP high-sensitivity human-cytokine kit 
(Millipore, Billerica, MA) using Luminex xMAP methodol-
ogy (Luminex, Austin, TX). In response to LPS, clear rises 
in levels of tumor necrosis factor-alpha (TNF-a), interleu-
kin-6 (IL-6), and IL-8, peaking between 1.5 and 2 hr after 
injection, were observed, confirming an inflammatory 
response to LPS (see Figs. 1a–1c).
Chemical assays
We conducted chemical assays of body-odor samples to 
assess the relative abundance of potentially odorous (i.e., 
volatile) compounds with gas chromatography–mass 
spectrometry (GC-MS; see GC-MS Analysis in the 
Supplemental Material for details).
Participants
Forty participants (28 women, 12 men; mean age = 26.2 
years, SD = 6.3) were recruited from the Karolinska 
Institutet university campus to take part in the body-
odor-assessment portion of the study. To be included, 
participants had to be nonsmokers and to have self-
reported good health and functional sense of smell.
Procedure
Using a double-blind, within-group experimental design, 
we tested participants separately with 18 unique odor 
stimuli (8 LPS body-odor samples, 8 placebo body-odor 
samples, and 2 samples from unworn T shirts, which 
served as controls) in squeeze bottles.
For each participant, the odor stimuli were first pre-
sented one at a time in a uniquely randomized order with 
an intertrial interval of 30 s. After a short break of 1.5 
min, the odor stimuli were presented a second time, 
again in a uniquely randomized order. On each trial, the 
participant could squeeze the bottle and smell the head-
space a maximum of two times to prevent sensory adap-
tation. After smelling the sample, they rated its perceived 
intensity (using a scale from 0 to 7), pleasantness (using 
a scale from −7 to 7), and health (using a scale from −4 
to 4). Unique scales were used to avoid the potential 
confound that participants would convert ratings from 
one scale to another. The extremes of the scales were 
referred to as “maximal experiences.” The value of 0 on 
the pleasantness and health scales was referred to as 
“neither pleasant nor unpleasant” and “neither healthy 
nor sick,” respectively. We used a measure of perceived 
intensity to assess whether there was a quantitative rather 
than qualitative difference between sick and healthy 
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body odors, and we used a measure of pleasantness 
because it is the primary dimension of the olfactory per-
ceptual space and is therefore at the base of olfactory 
functioning (Khan et al., 2007).
Results and Discussion
Participants’ ratings of the perceived intensity, pleasant-
ness, and health of odor samples from the three experi-
mental conditions (LPS, placebo, and control; see Fig. 2) 
were submitted to analyses. Control odors (unworn 
T-shirts) were rated as smelling significantly less intense, 
more pleasant, and healthier than the LPS and placebo 
odors (worn T-shirts; see Additional Analyses of Ratings of 
Control Shirts and Table S1 in the Supplemental Material), 
which indicates that the body-odor-sampling technique 
was adequate. Further analyses, therefore, were focused 
on the difference between LPS and placebo body odors. 
Linear mixed model analyses, using both donors and rat-
ers as statistical units (see Choice of Statistical Analysis of 
Body-Odor Ratings in the Supplemental Material for 
details) with Bonferroni-Holm correction for multiple test-
ing (Holm, 1979), showed that the LPS body odors smelled 
significantly more unpleasant, d = 0.259, t(592) = 4.487, 
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Fig. 1.  Mean levels of proinflammatory cytokines (a) tumor necrosis factor-alpha (TNF-a), (b) interleukin-6 (IL-6), and (c) IL-8 and 
(d) tympanic body temperature as a function of time after injection and treatment (lipopolysaccharide, LPS, vs. placebo). Error bars represent 
standard errors. 
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p < .001, more intense, d = 0.212, t(592) = 4.423, p < .001, 
and more unhealthy, d = 0.133, t(592) = 2.025, p = .043.
These results indicate that humans can indeed dissoci-
ate between the odors of sick and healthy individuals 
within 4 hr of innate immune-system activation; there are 
at least two possible reasons for this effect. The body 
odors of sick and healthy people may differ in perceived 
intensity, reflecting that the sick body emits more of the 
same types of volatile and odorous substances as the 
healthy body. The higher perceived intensity of the sick 
body-odor samples supports such a “more-of-the-same” 
model. The other possible, and more intriguing, explana-
tion for the LPS-induced changes in body odor is that the 
pattern of substance concentrations emitted from the 
body has changed and forms a cue of sickness, reflecting 
the activation of the innate immune system. Such a quali-
tative shift, independent of overall odorant concentra-
tion, would be a more ecologically viable candidate to 
modulate behavioral adaptations. The observation that a 
sick individual’s body odor smells more unpleasant and 
unhealthy supports such a “sickness-cue” model.
However, it is well established that odor pleasantness—
in addition to odor intensity—changes as a function of 
odorant concentration (Doty, 1975). Whereas intensity 
increases with odor concentration, pleasantness follows 
a more complicated model: Pleasant odors tend to have 
an optimum along the stimulus-concentration range, and 
unpleasant odors simply get more unpleasant as the con-
centration increases (Lawless, 1977). Given that body 
odors are on the unpleasant end of the olfactory contin-
uum (Fig. 2), we expect that an increase in body-odor 
intensity would be accompanied by an increase in unpleas-
antness. Hence, a more-of-the-same model could also pre-
dict a shift in odor pleasantness.
To answer the question of whether or not there was a 
treatment-related shift in body-odor pleasantness inde-
pendent of the changes in odor intensity, we performed 
an analysis similar to that used to assess the effect of 
body-odor type (LPS, placebo) on pleasantness ratings, 
but we added odor intensity as a covariate. The results 
showed a significant and separate effect of LPS treatment 
on body-odor pleasantness, d = −0.118, t(597) = 2.424, 
p = .016, and this effect could not be explained by differ-
ences in intensity. The same test of perceived health 
using intensity as a covariate did not reveal a significant 
separate effect of treatment, d = −0.046, t(598) = −0.730, 
p = .465.
Moreover, to directly test the more-of-the-same model, 
we analyzed the body-odor samples (using GC-MS) to 
assess the concentration of odorous compounds. Because 
the samples had been used in the behavioral test and 
were therefore potentially depleted and contaminated, 
the analysis was restricted to determining the overall 
abundance of volatile compounds in the LPS and placebo 
samples. The results indicated that the concentrations of 
the LPS samples were, on average, lower than those in 
placebo samples across all compounds identified, but 
insignificantly so, d = 0.134, t(16) = 0.715, n.s. In other 
words, LPS-treated participants did not seem to sweat 
more, but rather less, than those who were placebo 
treated. Thus, these results fail to support a more-of-the-
same model as the explanation of LPS-induced changes 
in body odor and are consistent with the notion that dur-
ing a generalized sickness response, humans emit a 
chemical cue. Dedicated studies should target these 
chemicals in the future.
In order to link the change in body-odor composition 
not only to the LPS treatment but also to the actual 
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Fig. 2.  Mean ratings of the perceived (a) intensity, (b) pleasantness, and (c) health of odors of T-shirts worn by individuals exposed to lipo-
polysaccharide (LPS) and a placebo. Error bars show standard errors. Asterisks indicate significant differences between conditions (*p < .05; 
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treatment-induced inflammatory response, we performed 
mediation analyses of cytokines. Cytokines IL-6 and 
TNF-a, but not IL-8, significantly mediated the effect 
of treatment on body-odor pleasantness and intensity 
(Table 1). Taken together, these results strongly support 
that humans emit a chemical cue during a generalized 
sickness response that can be perceived by others.
According to participants’ verbal reports, rating body-
odor intensity and pleasantness was an easier task 
than rating the perceived health of body-odor samples. 
Moreover, the effect size of LPS treatment on health rat-
ings, albeit significant, was relatively small. In fact, there 
was no significant effect of treatment on health ratings 
when either pleasantness or intensity was controlled for; 
thus, these results do not support a direct perception of 
health status. Instead, health ratings may have been 
based on inferences from the other aspects of the odor, 
such as its pleasantness. It has also been suggested that 
the emotion of disgust has evolved as a disease-avoid-
ance mechanism (Oaten, Stevenson, & Case, 2009). The 
current results may be relevant to this hypothesis, in that 
a disgust-driven, negative response promotes withdrawal 
from and avoidance of a sick individual by healthy ones. 
In concert with the social withdrawal exhibited by 
infected individuals, such mechanisms are modeled 
to be highly effective in containing an epidemic— 
particularly if instigated soon after infection (Cole, 2006). 
In this study, when participants rated body odors of 
“sick” individuals, they found them significantly more 
unpleasant than “healthy” body odors; future studies 
should focus on the role of disgust in such responses to 
“sick” body odor.
The exact nature of the cue or signal has yet to be 
determined. For instance, the volatile substances in the 
skin mediating the effect from an inflammatory response 
to body odor need careful investigation. Moreover, with 
regard to theory, there are two assumptions one can 
make about a sickness odor: It could be viewed as either 
a cue or a signal. As a cue, it would be inadvertent on 
behalf of the sender and beneficial to the receiver. In line 
with that notion, most animal studies have revealed 
avoidance behavior in response to a sick body odor. 
However, the avoidance behavior is typically seen in 
response to body odors of unfamiliar conspecifics; in 
contrast, increased maternal licking of LPS-treated rat 
pups has also been reported (Breivik et al., 2002). This 
pattern of results supports the idea that the sickness odor 
can also be a signal beneficial to the sender. Some evi-
dence even suggests that, rather than being aversive, the 
odor of infected males simply loses its attractiveness, 
which suggests a reduced signal of health rather than an 
increased signal of sickness (Kavaliers & Colwell, 1995a; 
Penn, Schneider, White, Slev, & Potts, 1998). It is not yet 
clear whether these changes are best characterized as a 
cue of illness beneficial to recipients or simply as a 
reduced signal of health from a sender whose resources 
necessary for health-signal maintenance have been real-
located (Penn & Potts, 1998). It should also be noted that 
the specificity of the type of olfactory cue indicated here 
and in animal models remains to be determined.
Among the physiological adaptations that occur after 
immune challenge is an activation of the hypothalamic-
pituitary-adrenal (HPA) axis (Maier, Watkins, & Nance, 
2001), and consequently, increased cortisol can be seen 
after LPS administration in humans (Grigoleit et al., 2011). 
This overlap between sickness and the fight-flight 
response is expected, given that mobilization and redi-
rection of energy is central to handling threats from both 
within and without (Segerstrom & Miller, 2004). Future 
studies should therefore investigate the extent to which 
internal and external challenges result in similar olfactory 
changes.
Table 1.  Crude and Mediated Effects on Ratings of Body-Odor Pleasantness, 
Intensity, and Health
Effect and mediator Pleasantness   Intensity Health
Crude effect  
  LPS –0.259 (0.058)*** 0.212 (0.048)*** –0.133 (0.066)*
  Temperature –0.120 (0.034)*** 0.091 (0.029)** –0.041 (0.039)
  IL-6 –0.181 (0.034)*** 0.145 (0.029)*** –0.080 (0.039)*
  IL-8 –0.144 (0.033)*** 0.107 (0.027)*** –0.059 (0.037)
  TNF-a –0.153 (0.031)*** 0.126 (0.026)*** –0.075 (0.035)*
Mediator of effects of LPS  
  IL-6 –0.149 (0.051)** 0.113 (0.043)* –0.049 (0.057)
  IL-8 –0.070 (0.061) 0.017 (0.051) 0.013 (0.068)
  TNF-a –0.154 (0.077)*a 0.127 (0.064)*,a –0.058 (0.085)
Note: Tests of the significance of mediation effects were conducted using Sobel tests and were 
based on MacKinnon and Fritz (2007). Standard deviations are shown in parentheses. LPS = 
lipopolysaccharide; IL-6 = interleukin-6; IL-8 = interleukin-8; TNF-a = tumor necrosis factor-
alpha.
aSignificance does not withstand a Bonferroni-Holm correction for multiple testing.
*p < .05. **p < .01. ***p < .001.
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Altogether, the results of this experimental study sug-
gest that, akin to rodents, humans are able to detect a 
social cue of sickness from body odor alone, which can be 
used for avoidance of infected conspecifics. Moreover, this 
social information can be triggered by the innate immune 
response, which is observable just a few hours after innate 
immune-system activation and is a general response to a 
variety of pathogens. Human olfaction may thus prove to 
be a signaling route to a “behavioral immune response” 
(Breivik et al., 2002) that protects healthy individuals by 
altering patterns of interpersonal contact and, possibly, by 
heightening the immune-system response to infection in 
the receiver, as has been shown for other disease-related 
stimuli (Schaller & Park, 2011; Stevenson et al., 2012).
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